{"id":"https://openalex.org/W134654650","doi":null,"title":"Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.","display_name":"Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis.","publication_year":2007,"publication_date":"2007-12-01","ids":{"openalex":"https://openalex.org/W134654650","mag":"134654650","pmid":"https://pubmed.ncbi.nlm.nih.gov/18050376"},"language":"en","primary_location":{"id":"pmid:18050376","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18050376","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010580345","display_name":"Helen G. Haggerty","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Helen G Haggerty","raw_affiliation_strings":["Immunotoxicology, Drug Safety Evaluation, Bristol-Myers Squibb, Syracuse, New York 13057, USA. helen.haggerty@bms.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immunotoxicology, Drug Safety Evaluation, Bristol-Myers Squibb, Syracuse, New York 13057, USA. helen.haggerty@bms.com","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013161124","display_name":"Mark A. Abbott","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark A Abbott","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112697229","display_name":"Timothy P. Reilly","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Timothy P Reilly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000555475","display_name":"Deborah A DeVona","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Deborah A DeVona","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045181712","display_name":"Carol R. Gleason","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carol R Gleason","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053931033","display_name":"Lee K. Tay","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lee Tay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069881279","display_name":"Robert W. Dodge","orcid":"https://orcid.org/0000-0001-6653-9701","observed_orcids":["https://orcid.org/0000-0001-6653-9701"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Dodge","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5107848786","display_name":"Richard Aranda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Richard Aranda","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.437,"has_fulltext":false,"cited_by_count":59,"citation_normalized_percentile":{"value":0.80421157,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"34","issue":"12","first_page":"2365","last_page":"73"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.5009999871253967,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.5009999871253967,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.46880000829696655,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.007400000002235174,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/abatacept","display_name":"abatacept","score":1.0},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.9589999914169312},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9760000109672546},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9089999794960022},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.7639999985694885},{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.7490000128746033},{"id":"https://openalex.org/keywords/antibody-response","display_name":"antibody response","score":0.5329999923706055},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.718999981880188},{"id":"https://openalex.org/keywords/loss-of-efficacy","display_name":"loss of efficacy","score":0.6029999852180481},{"id":"https://openalex.org/keywords/seroconversion","display_name":"seroconversion","score":0.5429999828338623}],"concepts":[{"id":"https://openalex.org/C2779605438","wikidata":"https://www.wikidata.org/wiki/Q2697833","display_name":"Abatacept","level":4,"score":0.9584836959838867},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8945913910865784},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.8791580200195312},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.8035081028938293},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.6049146056175232},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5607760548591614},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.5116291642189026},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.49951958656311035},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.4829920530319214},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3573046922683716},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000069594","descriptor_name":"Abatacept","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D004797","descriptor_name":"Enzyme-Linked Immunosorbent Assay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":3,"locations":[{"id":"pmid:18050376","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18050376","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of rheumatology","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.1006.3112","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1006.3112","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://www.jrheum.org/content/34/12/2365.full.pdf","raw_type":"text"},{"id":"mag:134654650","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18050376","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2079359234","https://openalex.org/W2065199309","https://openalex.org/W146632862","https://openalex.org/W2156240435","https://openalex.org/W1838152093","https://openalex.org/W2126049604","https://openalex.org/W2981814136","https://openalex.org/W2148544753","https://openalex.org/W2129479019","https://openalex.org/W2326251088"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1],"immunogenicity":[2,204,281],"of":[3,108,147,203,260,264,280],"abatacept,":[4],"a":[5,61,200,277],"selective":[6],"costimulation":[7],"modulator,":[8],"administered":[9],"intravenously,":[10],"was":[11,68,253,274],"assessed":[12],"across":[13],"Phase":[14,49,54,180],"II":[15,50],"and":[16,38,41,57,76,92,114,186,258,267,286],"III":[17,55,181],"trials":[18,56],"in":[19,47,178,282],"patients":[20,110,126,149,176,206,217,234,283],"with":[21,89,111,227,240,276,284],"rheumatoid":[22],"arthritis":[23],"(RA).":[24],"METHODS:":[25],"Two":[26],"direct-format":[27],"enzyme-linked":[28],"immunosorbent":[29],"assays":[30],"evaluated":[31,177],"antibody":[32,153,256],"responses":[33],"[whole":[34],"abatacept":[35,158],"molecule":[36,159],"(CTLA-4":[37],"Ig":[39],"portion)":[40],"CTLA-4":[42,166],"portion":[43,167],"only":[44],"(Assay":[45],"A)]":[46],"the":[48,53,82,141,156,165,173,179,228],"trials.":[51],"During":[52],"2-year":[58],"open-label":[59],"periods,":[60],"similar,":[62],"but":[63],"more":[64,142],"sensitive,":[65],"Assay":[66,136,144],"B":[67],"employed.":[69],"Serum":[70],"samples":[71,88,117],"collected":[72,189],"prestudy,":[73],"during":[74],"treatment,":[75],"56":[77,190],"and/or":[78,191],"85":[79,192],"days":[80,193],"following":[81],"last":[83],"dose":[84],"were":[85,97,118,223],"evaluated.":[86],"Seropositive":[87],"anti-CTLA-4":[90,131,220],"reactivity":[91],"sufficiently":[93],"low":[94,278],"drug":[95],"levels":[96],"further":[98],"characterized":[99],"for":[100,120,219,225],"neutralizing":[101,236],"activity":[102],"(cell-based":[103],"bioassay).":[104],"RESULTS:":[105],"A":[106,137],"total":[107],"2237":[109],"both":[112],"pre-":[113],"post-baseline":[115],"serum":[116],"eligible":[119,224],"assessment.":[121],"Of":[122,172,215,231],"these,":[123,232],"62":[124],"(2.8%)":[125],"demonstrated":[127,151],"an":[128,152],"anti-abatacept":[129],"or":[130,138,164,245],"response,":[132],"determined":[133],"using":[134],"either":[135],"B.":[139],"Using":[140],"sensitive":[143],"B,":[145],"60":[146],"1990":[148],"(3.0%)":[150],"response":[154,257],"to":[155],"whole":[157],"(n":[160,168],"=":[161,169],"41,":[162],"2.1%)":[163],"19,":[170],"1.0%).":[171],"1764":[174],"RA":[175,285],"studies,":[182],"203":[183],"discontinued":[184,198],"therapy":[185],"had":[187,199],"sera":[188],"after":[194],"discontinuation.":[195],"Patients":[196],"who":[197,207],"higher":[201],"incidence":[202,279],"versus":[205],"did":[208],"not":[209],"discontinue":[210],"(7.4%":[211],"vs":[212],"2.6%,":[213],"respectively).":[214],"20":[216,266],"positive":[218],"reactivity,":[221],"13":[222],"assessment":[226],"neutralization":[229],"bioassay.":[230],"8":[233],"exhibited":[235],"activity.":[237],"Seroconversion":[238],"occurred":[239],"no":[241],"adverse":[242,289],"safety":[243],"outcomes":[244],"effect":[246],"on":[247],"pharmacokinetic":[248],"parameters.":[249],"No":[250],"consistent":[251],"pattern":[252],"observed":[254],"between":[255],"loss":[259],"efficacy":[261],"(American":[262],"College":[263],"Rheumatology":[265],"Health":[268],"Assessment":[269],"Questionnaire":[270],"responses).":[271],"CONCLUSION:":[272],"Abatacept":[273],"associated":[275],"lacked":[287],"any":[288],"sequelae.":[290]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}